François Bécher

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

Nicolas R. Barthélemy, Randall J. Bateman, Christophe Hirtz et al. · Alzheimer s Research & Therapy · 2020 · 246 citations · Full text

Immunopurification and Mass Spectrometric Quantification of the Active Form of a Chimeric Therapeutic Antibody in Human Serum

Mathieu Dubois, François Fenaille, Gilles Clément et al. · Analytical Chemistry · 2008 · 143 citations

Immunocytochemical Technique, Immunology, Pathology +20

Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies

Nicolas R. Barthélemy, Audrey Gabelle, Christophe Hirtz et al. · Journal of Alzheimer s Disease · 2016 · 142 citations · Full text

Immunology, Biological Mass Spectrometry, Neurochemical Biomarkers +25

Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity

Nicolas R. Barthélemy, François Fenaille, Christophe Hirtz et al. · Journal of Proteome Research · 2016 · 120 citations

Human Cerebrospinal Fluid, Molecular Biology, Pathology +17

Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral‐blood mononuclear cells using high‐performance liquid chromatography/tandem mass spectrometry

François Bécher, Alain Pruvost, Cécile Goujard et al. · Rapid Communications in Mass Spectrometry · 2002 · 94 citations